

CVS HEALTH Corp
Form 8-K
May 18, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 16, 2016

CVS HEALTH CORPORATION
(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-01011
(Commission
File Number)

05-0494040
(IRS Employer
Identification No.)

One CVS Drive

Woonsocket, Rhode Island
(Address of Principal Executive Offices)

02895
(Zip Code)

Registrant's telephone number, including area code: (401) 765-1500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On May 16, 2016, CVS Health Corporation, a Delaware corporation (the *Company*), entered into an Underwriting Agreement (the *Underwriting Agreement*) with Barclays Capital Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representatives of the several underwriters named in Schedule I thereto (the *Underwriters*), pursuant to which the *Company* agreed to issue and sell to the *Underwriters* \$1,750,000,000 aggregate principal amount of its 2.125% senior notes due June 1, 2021 (the *2021 Notes*) and \$1,750,000,000 aggregate principal amount of its 2.875% senior notes due June 1, 2026 (the *2026 Notes*, and together with the *2021 Notes*, the *Notes*). The *Notes* were offered pursuant to the *Company*'s Registration Statement on Form S-3, File No. 333-210872, dated May 4, 2016.

From time to time, certain of the *Underwriters* and/or their respective affiliates have directly and indirectly engaged, and may engage in the future, in investment and/or commercial banking transactions with the *Company* for which they have received, or may receive, customary compensation, fees and expense reimbursement. Barclays Capital Inc. is acting as Dealer Manager in connection with the *Company*'s cash tender offers (the *Tender Offers*) for (1) any and all of its 5.75% Senior Notes due 2017, its 6.60% Senior Notes due 2019 and its 4.75% Senior Notes due 2020 and (2) up to \$1,500,000,000 aggregate principal amount of its 6.25% Senior Notes due 2027, its 6.125% Senior Notes due 2039, its 5.750% Senior Notes due 2041, the 5.00% Senior Notes due 2024 issued by its wholly-owned subsidiary, Omnicare, Inc. (*Omnicare*), the 4.75% Senior Notes due 2022 issued by Omnicare, its 4.875% Senior Notes due 2035 and its 3.875% Senior Notes due 2025. To the extent any of the *Underwriters* or their affiliates own notes that are the subject of the *Tender Offers*, they may tender such notes pursuant to the terms of the *Tender Offers*. An affiliate of one of the *Underwriters*, BNY Mellon Capital Markets, LLC, is the trustee, registrar and paying agent for the *Notes*. Additionally, a member of the *Company*'s board of directors is an officer of Bank of America Corporation, an affiliate of one of the *Underwriters*.

The closing of the sale of the *Notes* will occur on May 25, 2016, subject to the satisfaction of customary closing conditions contained in the *Underwriting Agreement*. The net proceeds to the *Company* from the sale of the *Notes*, after deducting the *Underwriters*' discounts and the estimated offering expenses payable by the *Company*, are approximately \$3,454,795,000.

A copy of the *Underwriting Agreement* is filed as Exhibit 1.1 to this report on Form 8-K and is incorporated by reference into the Registration Statement.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

- 1.1** Underwriting Agreement dated May 16, 2016 between CVS Health Corporation and Barclays Capital Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representatives of the several underwriters named in Schedule I thereto

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CVS HEALTH CORPORATION

By: /s/ David M. Denton
David M. Denton
Executive Vice President and
Chief Financial Officer

Dated: May 18, 2016